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Abstract: Since the discovery of WNK mutations causing an inherited 
form of hypertension in humans, there has been an increasing interest 
in targeting WNK-signaling as a novel strategy for modulating blood 
pressure. This notion is now supported by numerous mouse models 
with impaired WNK-signaling that exhibit reduced blood pressure. 
Biochemical analyses of the different protein components making up 
this signaling pathway have identified a number of plausible molecular 
targets that are amenable to targeting by small molecules. To date, a 
selection of small molecule WNK-signaling inhibitors have been 
identified and have shown promise in suppressing the activity of 
WNK-signaling in cells and in animals. In this Minireview, we will 
briefly discuss the WNK-signaling pathway and provide an overview 
the various druggable targets within this cascade as well as the 
different WNK-signaling inhibitors discovered to date. 
1. Introduction 
Hypertension (high blood pressure) is the most common chronic 
disorder seen in primary care. It affects more than a billion people 
worldwide and represents a major risk factor for various disabling 
and fatal diseases such as stroke and heart failure.[1] Although 
current antihypertensive therapies have been very useful in 
controlling blood pressure, the emergence of resistance to these 
drugs, termed resistant hypertension, is being noted as global 
challenge in treating hypertension.[1] Furthermore, intolerance 
and allergies to some of the current approved antihypertensive 
drugs has limited their use. Together, these contributed to an 
emerging need for novel antihypertensive drugs.  
Among the key signaling pathways that are implicated in the 
regulation of blood pressure in vivo is the WNK-signaling 
cascade.[2] The first link between this signaling pathway and 
hypertension came in 2001 when it was discovered that mutations 
in the genes that encode WNK kinases caused an inherited form 
of hypertension in humans known as Gordon’s syndrome.[3] The 
first insight into the molecular mechanism by which the WNK 
Serine/Threonine protein kinases regulate blood pressure came 
when it was discovered that they bind and phosphorylate two 
other Serine/Threonine protein kinases termed SPAK and OSR1 
resulting in their activation (Figure 1).[4] Indeed, WNK kinases 
phosphorylate SPAK and OSR1 at a highly conserved Threonine 
on their T-loops, Thr233 and Thr185 respectively.[4a] Although 
additional WNK-phosphorylation sites on SPAK and OSR1, 
mainly on their C-terminal domains were also been identified, the 
function of these phosphorylation sites remains not fully 
understood.[4a] Upon their phosphorylation by WNK kinases, 
SPAK and OSR1 subsequently bind to a scaffolding protein 
termed MO25 resulting in a significant activation of SPAK and 
OSR1, 80- and 100-fold respectively.[5] Active SPAK and OSR1 
in complex with MO25 subsequently phosphorylate a series of 
sodium (Na+), potassium (K+) and chloride (Cl-) ion co-
transporters, e.g. the Na+-K+-Cl- co-transporter (NKCC) 1 and 2, 
the Na+-Cl- co-transporter (NCC) and K+-Cl- co-transporter (KCC) 
(Figure 1).[6] Notably, the phosphorylation of these ion co-
transporters by SPAK and OSR1 kinases can lead to either their 
activation or inhibition and hence influencing electrolyte balance, 
which is ultimately translated into changes in blood pressure.[2, 6]  
A more recent link between WNK-signalling and hypertension 
was reported when humans with genetic mutations in two E3 
ubiquitin ligases known as KLHL3 and Cul3 had Gordon’s 
syndrome.[7] Subsequent work showed that both KLHL3 and Cul3 
regulate the total protein levels of WNK kinases and thus the 
observed phenotype was a result of impairing WNK-signalling.[8] 
A more detailed account of the WNK-SPAK/OSR1-MO25 
signalling pathway can be found in recent reviews by Alessi DR 
et al[6] and Hadchouel J et al[9].  
The involvement of WNK-SPAK/OSR1-MO25 signalling in 
regulating blood pressure through the modulation of electrolyte 
balance in vivo suggested that this signalling pathway could be 
targeted in the discovery of new antihypertensive drugs. To test 
this hypothesis, numerous mouse models were generated and 
these exhibited Gordon’s syndrome-like symptoms.[2] Among the 
earlier mouse models were SPAK knock-in and knock out mouse 
models, which exhibited reduced blood pressure and reduced 
phosphorylation of SPAK physiological substrates e.g. NKCC1.[10] 
These mouse models as well as later ones provided strong 
evidence for the targeting of WNK-signalling with small molecules 
in the discovery of new antihypertensive agents. These various 
SPAK and OSR1 mouse models  have recently been reviewed by 
Murthy M. et al[2].  
Given that the link between WNK-signalling and hypertension was 
reported in 2001 and early knock-in mouse models of this 
signalling pathway appeared in mid 2006, the discovery of small 
molecules that target this signalling pathway has been relatively 
slow. Indeed, the first report of small molecules that inhibit WNK-
signalling appeared in 2013.[11] Since then, the discoveries of 
[a] Mubarak A. AlAmri, Shumail Mahmood, Abdulrahman Elzwawi  
School of Pharmacy 
College of Medical and Dental Sciences 
           University of Birmingham 
           Edgbaston, Birmingham (UK) 
[b] Dr. Hachemi Kadri, Binar Dhiani and Dr. Youcef Mehellou  
School of Pharmacy and Pharmaceutical Sciences 
College of Biomedical and Life Sciences 
           Cardiff University (UK) 
           E-mail: MehellouY1@cardiff.ac.uk  
          
 
 
 
 
 
numerous small molecules that inhibit WNK-signalling by 
targeting various molecular targets within the WNK-signalling 
have been reported. Herein, we discuss the different strategies 
used for inhibiting WNK-signalling and the various WNK-
signalling inhibitors that have been reported to date.   
 
2. Strategies for inhibiting WNK-signaling 
Considering the WNK-signalling pathway illustrated in Figure 1, 
four different molecular targets for inhibiting this cascade, as 
discussed below, have been exploited and yielded interesting 
small molecule WNK-signalling inhibitors.  
2.1. Inhibitors of WNK kinases 
Kinase inhibitors, which are classically divided into ATP 
competitive and non-ATP competitive inhibitors, have been very 
powerful pharmacological tools and useful agents in treating 
many diseases.[12] Since the cornerstone of the WNK-signalling 
pathway are the WNK protein kinases, it was only a matter of time 
until kinase inhibitors of WNKs were reported. However, it took 
almost 15 years from the discovery of WNK mutation causing 
hypertension in humans to the first report on the discovery of 
WNK kinase inhibitors.[13]  
2.1.1. WNK ATP-competitive kinase inhibitors 
Unlike other protein kinases, WNK kinases are known by the 
unusual placement of the catalytic lysine residue (Lys233) within 
their ATP binding site (Figure 2a). The crystal structure of inactive 
WNK1 Ser382Ala, in which autophosphorylation and activation is 
prevented by mutation of S382 into alanine indicated that the 
common catalytic lysine’s position in strand β3 (subdomain II) in 
most kinases was occupied by a cysteine residue (Cys250) in 
WNK1 (Figure 2a and b).[14] The catalytic residue normally binds 
to the α and β phosphate groups of ATP molecules and 
contributes along with the glycine-rich loop in stabilising the ATP 
molecule in the active site. Moreover, it forms salt-bridge with the 
adjacent glutamate residue in helix C, which contributes to the 
shape of the ATP binding site. However, in WNK1, the catalytic 
lysine (Lys233) residue exists in the glycine-rich loop in strand β2 
(subdomain I) and is 13 Å away from the glutamate residue 
(Glu268) in helix C. Therefore, a large cavity in the back of the 
binding site near a cysteine residue (Cys250) is present.[14]  
This unique structural feature was exploited in the targeting of this 
family of kinases to discover highly selective inhibitors that target 
their ATP binding site. Indeed, the discovery of the first selective 
small molecule pan-WNK kinases inhibitor has recently been 
reported.[13a] High throughput screening of about 1.2 million 
compounds from the Novartis compound archive identified hit 1 
(IC50 = 856 nM) as a promising inhibitor of WNK1 in vitro (Figure 
2c). Further medicinal chemistry efforts and optimisation of this 
hit compound led to the more potent inhibitor WNK463, which 
showed potent inhibition of the four isoforms of WNK kinases 
(WNK1 IC50 = 5 nM, WNK2 IC50 = 1 nM, WNK3 IC50 = 6 nM, WNK4 
IC50 = 9 nM) (Figure 2c). Notably, WNK463 showed potent 
inhibition of endogenous WNK kinases in HEK293 cells, IC50 = 
106 nM.[13a]  
Figure 1. A depiction of the WNK-SPAK/OSR1 signalling pathway. The two E3 ubiquitin ligases KLHL3 and Cul3 mediate the ubiquitylation of WNK 
kinases that leads to their degradation. WNK kinases, isoforms 1-4, phosphorylate SPAK and OSR1 kinases on their T-loops, Thr233 and Thr185 
respectively. Subsequently, SPAK and OSR1 bind the adaptor protein MO25, of which in humans there are two isoforms α and β. Active SPAK and 
OSR1 in complex with MO25 phosphorylate a selection of sodium, potassium and chloride co-transporters at different residues as shown. Such 
phosphorylation influences the function of these ion co-transporters resulting in changes in electrolyte balance, which ultimately manifests itself in changes 
in blood pressure levels. The different strategies (1-4) that are currently employed in the discovery of WNK-signalling inhibitors are highlighted. Ub: 
ubiquitin. CCT: conserved C-terminal.  
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WNK463 exhibited high selectivity for WNK kinases in that even 
at a relatively high screening concentration of 10 μM, only two out 
of the 442 human kinases studied showed inhibition > 50%. The 
co-crystal structure of WNK463 with WNK1 kinase domain 
WNK463 indicated that it binds to WNK kinases with high affinity 
regardless of their phosphorylation state. Indeed, the crystal 
structure of the WNK1 S382A catalytic domain in complex with 
WNK463 (PDB code: 5DRB) is generally similar to the one 
reported for apo-WNK1 Ser382Ala kinase domain. Interestingly, 
the solved co-crystal structure also revealed that WNK463 has a 
unique binding way in that it binds to the hinge part of the ATP 
pocket and extends toward a nearby WNK-specific back pocket 
through a narrow tunnel which arises from the nonstandard 
placement of the catalytic lysine (Lys233) in the glycine-rich loop 
(Figure 2d).[13a] 
Given the impressive in vitro potency and selectivity of the pan-
WNK kinases inhibitor WNK463, it was subsequently studied in 
vivo. Oral dosing of spontaneously hypertensive rats (SHRs) with 
1, 3, or 20 mg/kg led to a dose-dependent decrease in blood 
pressure and simultaneous increases in heart rate.[13a] 
Additionally, significant dose-dependent increases in urine output 
along with urinary sodium and potassium excretion rates were 
observed.[13a] In transgenic mice overexpressing human WNK1, 
oral dosing of WNK463 again resulted in a significant reduction in 
blood pressure in these hypertensive mice.[13a] Notably, kidney 
lysate samples from these mice showed a dose-dependent 
decrease in the phosphorylation of SPAK and OSR1, the 
physiological substrates of WNK kinases.[13a] This provided a 
strong evidence of the observed reduction in blood pressure was 
a result of the in vivo inhibition of WNK kinases.  
Despite the promising in vitro and in vivo efficacy and selectivity 
profile of WNK463, the development of WNK463 into a potential 
antihypertensive agent was discontinued due to pre-clinical safety 
profile issues. A possible explanation for this would be the 
ubiquitous expression of some WNK kinases, especially WNK1, 
and the lack of selectivity of WNK463 across the four WNK 
isoforms, which may be involved in key physiological processes 
beyond those relating directly to the regulation of blood pressure. 
 
2.1.2. WNK allosteric kinase inhibitors 
Beyond ATP-competitive WNK kinase inhibitors, the Novartis 
group also discovered allosteric WNK kinase inhibitors.[13b] 
Allosteric modulation of protein kinases can ensure better 
selectivity profile for the inhibitor by targeting the less conserved 
regions in the kinase compared to the highly conserved ATP 
binding pocket. Since there were no structural information 
available about allosteric sites on WNK kinases, which regulate 
their catalytic activity, and hence enable the rational design of 
inhibitors, efforts were directed towards the use of high throughput 
screening at high ATP concentrations with the premise of 
targeting allosteric sites that may exist in other conformational 
states.  
Using a higher ATP concentration (100 µM, 2-fold above Km), a 
single-point screening of the 1.2 million compounds from the 
Figure 2. Discovery and development of ATP-competitive WNK kinase inhibitors. A) Sequence alignment of the ATP-binding pockets of the four human 
isoforms of WNK kinases. Residues making up the ATP binding site are highlighted in light orange. The catalytic lysine residue, Lys233 for WNK one 
and the corresponding ones for WNKs 2-4, are highlighted in light pink. Other key amino acid residues namely Cys250 and Glu268 for WNK1 and those 
of the corresponding WNK isoforms are highlighted in green and purple respectively. Human WNK isoforms sequences were obtained from uniprot.org 
and the sequence alignment was conducted using MUSCLE. B) ATP binding pocket of WNK1 kinase showing the positions of key amino acid residues 
and structural motifs. C) Optimisation of the initial HTS hit into WNK463 with their potency of inhibiting WNK kinase isoforms in vitro. The kinase activity 
was measured either using MBP (a) or OSR1 (b) as a substrate. D) Co-crystal structure of WNK463 with WNK1 kinase domain (PDB code: 5DRB). 
Docking figures were produced by AutoDock Vina. Data shown in C was taken from Yamada K et al.[13a]  
          
 
 
 
 
 
Novartis compound archive at 50 µM concentration was first 
performed.[13b] This resulted in an initial hit list of 8257 compounds 
(0.8% hit rate), which exhibited > 30% inhibition of WNK1. This 
list was then filtered and sorted using known structural data about 
kinase inhibitors and in silico approaches to reduce the number of 
hits to 2298 compounds. Further hit validation through 
determination of potency and priotarisation based on cellular Elisa 
assays narrowed the list of candidates down to compound 1 
(Figure 3a). This compound was considered a promising starting 
point as it showed a good selectivity profile for WNK1 kinase 
across a 31 Novartis in-house kinase panel. Structural 
optimization of this hit led to compound 2, which was found to be 
highly selective inhibitor of WNKs 1-4 with a consistent IC50 = 
0.570 µM at various ATP concentrations suggesting its binding to 
an allosteric site in the WNK kinases (Figure 3a). 
The crystal structure of compound 2 bound to WNK1 revealed the 
formation of a novel ligand-induced allosteric pocket proximal to 
the ATP binding site (Figure 3b).[13b] The binding of compound 2 
to WNK1 was found to trigger an outward movement of αC-helix 
and stretching of the activation loop from the Apo-WNK1 to form 
this allosteric site displaying a type III-like allosteric binding mode. 
Subsequently, a cellular assay was developed using rubidium as 
a surrogate for cellular potassium uptake to determine the effects 
of WNK inhibition by compound 2 on cellular electrolyte handling. 
In the HT29 cells, compound 2 produced a more potent dose 
dependant inhibition of rubidium uptake by the NKCC1 ion co-
transporter with an IC50 of 0.24 μM compared to the direct NKCC1 
blocker, Bumetanide which showed an IC50 of 1.54 μM.
[13b] 
Interestingly, compound 2 did not inhibit OSR1 even at a relatively 
high concentration of 10 μM indicating its selectivity for WNK 
kinases. Despite the encouraging potency and selectivity of 
compound 2 (and some of its analogues), the pharmacokinetic 
(PK) profile of this compound did not support further in vivo 
efficacy studies. Nevertheless, this compound and its analogues 
inspired the discovery of better lead compounds that exhibited 
potent efficacy and selectivity, which together permitted their in 
vivo testing. Indeed, extensive structure-activity relationship of 
compound 2 led to the discovery of compound 3 (Figure 3c).[15] 
This compound exhibited low nanomolar non-ATP competitive 
inhibition of WNK kinases in vitro though the compound had high 
microsomal clearance. Still, compound 3 showed excellent 
selectivity when tested at 10 µM in a panel of 440 human kinases 
with few significant off-targets that include Burton’s tyrosine 
kinase (BTK) and feline encephalitis virus-related (FER) 
kinase.[15] Interestingly, compound 3 showed ca. 1000-fold 
selectivity for WNK1 vs. WNK4 and 57-fold selectivity for WNK1 
vs. WNK2.[15] In vivo data in rats indicated the compound 3 had 
moderate clearance and low bioavailability. This was 
hypothesised to be a result of N-demethylation yielding the N-
methylaminothiazole derivative of 3, which itself had been noted 
to be chemically unstable in solution.[15] As means of addressing 
this, the perdeuteromethyl analogue of compound 3, referred to 
as compound 4 (Figure 3c), which was thought to possess better 
a PK profile, was prepared and studied. In rat PK studies, this 
compound showed low clearance and a 2-fold improvement in 
bioavailability compared to compound 3.[15]  
When single dosed orally in mice overexpressing human WNK1 
at 10, 30 and 100 mg/kg, compound 4 showed dose-dependent 
reduction in systolic blood pressure in terms of peak and time-
weighted average vs. baseline.[15] Also, single ascending oral 
doses of compound 4 (vehicle, 10, 30 then 100 mg/kg) given in 
successive days in SHRs resulted in dose-dependent diuresis, 
natriuresis and kaliuresis in rats dosed from 10 to 100 mg/kg.[15]  
The discovery of these various small molecule WNK kinases 
inhibitors indicates that these protein kinases are amenable to 
being targeted by small molecules. Indeed, such approach can 
lead to potent and selective WNK kinase inhibitors though 
achieving selectivity within the four WNK isoforms appears to be 
a difficult challenge. This may prove to be the bottleneck in the 
discovery of WNK kinase inhibitors as antihypertensive agents. In 
fact, the lack of the small molecules’ selectivity across the WNK 
isoforms may have contributed to the observed undesired side 
effects of these compounds in vivo especially those associated 
with ATP-competitive WNK kinase inhibitors, e.g. WNK463[13a]. 
2.2. Inhibitors of WNK binding to SPAK/OSR1 kinases 
Despite the fact that targeting protein-protein interactions (PPIs) 
is a stern challenge,[16] this approach is growing exponentially as 
a modern tool in target-based drug discovery and several PPIs 
Figure 3. Discovery and optimisation of a WNK kinases allosteric 
inhibitor. A) Chemical structure of the initial HTS hit and the optimised 
structure compound 2. The in vitro kinase inhibition potency of these 
compounds was measured using an OSR1 peptide as a substrate.  
Cellular activity was measured by blotting for OSR1 phosphorylation at 
Ser325, which is a WNK phosphorylation site. Data was taken from 
Yamada K et al.[13b] B) Co-crystal structure of compound 2 with WNK1 
kinase domain (PDB code: 5TF9). Figure produced by AutoDock Vina. 
Data in C was taken from Yamada K et al.[15]  
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modulators undergo clinical trials as treatments for different 
diseases.[17] Exploiting this approach, Uchida and colleagues[11] 
run a screen of 17,000 compounds aimed at identifying molecules 
that inhibit WNK binding to SPAK and OSR1 kinases. This work 
benefited from earlier studies that identified the highly conserved 
C-terminal domain of SPAK and OSR1 being responsible for 
mediating their binding to WNK kinases.[18] In particular the finding 
that a small tetrapeptide motif RFxV or RFxI that is present in 
WNK kinases and various ion co-transporters binds SPAK and 
OSR1 C-terminal domains.[18-19] Inspired by this, Uchida and co-
workers[11] labelled with a fluorophore, TAMARA, an 18-mer 
RFQV peptide derived from WNK4 and used  a fluorescent 
correlation spectroscopy method to measure its binding to GST-
tagged C-terminal domain of human SPAK (442–545). 
This high-throughput screening exercise resulted in the discovery 
of the first two WNK-SPAK binding modulators known as 
STOCK1S-50699 (IC50 = 37 µM, Kd = 32 µM) and STOCK2S-
26016 (IC50 = 16 µM, Kd = 20 µM) (Figure 4).
[11] These compounds 
possessed different chemical scaffolds and were able to bind to 
SPAK C-terminal domain and disrupt its binding to WNK1 and 
WNK4 RFQV peptides in vitro.[11] In cells, these inhibitors were 
able to inhibit WNK-SPAK/OSR1 phosphorylation of the ion co-
transporter NKCC1 at low micromolar concentrations.[11]  
 
Figure 4. Chemical structures, in vitro inhibition potency and binding 
affinities of reported small molecules that inhibit WNK binding to 
SPAK/OSR1. Data was taken from Mori T et al.[11] 
 
Since this report in 2013, STOCK1S-50699 has been widely used 
in subsequent studies as a WNK-signalling inhibitor as compared 
to STOCK2S-26016 despite its undrug-like properties. Notably, 
investigations into the in vitro selectivity of STOCK1S-50699 
showed it to have a good selectivity when tested at a single 10 µM 
concentration against a panel of 150 kinases.[20] Interestingly, the 
study by Mori et al[11] revealed a key detail of the structure activity 
relationship of STOCK2S-26016 as it was shown that the 
substitution of the flexible methylfuran moiety into a rigid smaller 
non-hydrophobic moiety, e.g. compound B1 (Figure 4), led to loss 
of activity.[11] As there is no crystal structure of SPAK or OSR1 C-
terminal domain in complex with these inhibitors, it has not been 
clear why such modification has strong influence on their kinase 
inhibition properties.  
Nevertheless, in a recent study[21], derivatives of STOCK2S-
26016 with modifications mostly in the 2-furanylmethylamino as 
well as the ethoxy and amino positions has revealed some 
interesting structure-activity relationship. Indeed, a series of 21 
compounds were synthesised out of which six exhibited better 
inhibition potency of WNK binding to SPAK/OSR1 than the parent 
compound STOCK2S-26016 ( (Figure 5).[21] 
First, the substitution of the methylfuran side group of STOCK2S-
26016 to para-substituted benzamidine moiety was tolerated and 
resulted in potent inhibitors of SPAK/OSR1 binding to WNK (e.g. 
analogues 1 and 2, Figure 5).[21] In particular, electron 
withdrawing groups gave the most potent inhibitors. Similarly, 
introducing a (4-cyanophenyl)urea functionality instead of the 
methylfuran group was also tolerated and led to potent inhibitors 
of SPAK/OSR1 binding to WNK.[21] The switching of the side chain 
ethoxy group of the parent compound STOCK2S-26016 into a 
methoxy or an unmasked hydroxyl did not seem to alter the 
biological activity too much, e.g. analogues 5 and 6 (Figure 5), as 
the compounds was comparable to analogues 1 and 2.[21] 
However, the most striking structure-activity relationship from this 
study was observed with analogues 3 and 4. Indeed, the 
replacement of the methylfuran side group of STOCK2S-26016 
with 4-cyanobenzamidine functionality and the side amino group 
to either a hydrogen of a phenoxy group led to a loss of biological 
activity. Since one of the analogues (structure not shown), which 
had only one change from the parent compound, a 4-
cyanobenzamidine functionality instead of the methylfuran group, 
showed good inhibition of SPAK/OSR1 binding to WNK (IC50 = 
6.9 μM), the lack of activity observed with analogues 3 and 4 could 
be attributed to the replacement of the side ammine group by 
other functionalities that are either bulkier or do not act as 
hydrogen bond acceptors. This suggests that the amine group is 
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Figure 5. Chemical structures of STOCK2S-26016 and its analogues as 
well as their potency of inhibiting WNK binding to SPAK/OSR1 in vitro. 
Data taken from Ishigami-Yuasa et al.[21]  
          
 
 
 
 
 
forming key interactions with an amino acid residue on SPAK CCT 
domain. As there is no co-crystal structure of any of these 
compounds with SPAK or OSR1 CCT domain, the identity of this 
amino acid residue remains unknown. 
Although the binding of these compounds by-design is the 
(primary) pocket where the RFQV peptide from the upstream 
WNK kinases dock (Figure 6),[22] it was recently suggested that 
these compounds may also bind an adjacent pocket termed the 
secondary pocket.[23]  
 
 
This observation was made when STOCK-1S50699 was able to 
inhibit constitutively active full length OSR1 Thr185Glu in vitro, 
IC50 = 40.25 µM.
[23]
 Molecular docking studies supported the 
preference of STOCK1S-50699 binding to the secondary pocket 
as opposed to the primary pocket of OSR1 C-terminal domain.[23] 
Interestingly, the binding of the 18-mer RFQV peptide derived 
from WNK4 to SPAK and OSR1 was not affected by STOCK1S-
50699 supporting the notion that this binds to the secondary 
pocket of SPAK and OSR1 kinases and hence may act as an 
allosteric inhibitor of these two important protein kinases.[23] Such 
suggestion needs to be confirmed by a crystal structure of SPAK 
or OSR1 C-terminal domain in complex with this compound 
though this remains unreported. 
2.3. Inhibitors of SPAK/OSR1 kinases  
As various SPAK mouse models have indicated the inhibition of 
this kinase as a viable strategy in lowering blood pressure,[10] it 
has (along with its closely related kinase OSR1) been an 
attractive target in the discovery of new antihypertensive agents. 
Although the crystal structure of SPAK is yet to be reported, the 
crystal structures of OSR1 C-terminal domain and OSR1 kinase 
domain were reported in 2007[22] and 2008[24], respectively. 
Despite such information that could aid rational drug design, the 
first SPAK and OSR1 kinase inhibitors were only reported in 
2015[25]. 
For this, the Uchida lab developed an ELISA assay for measuring 
the phosphorylation of human NKCC2 (residues 1-174) by 
SPAK.[25] This assay was subsequently used in screening a library 
of small molecules that consists of > 20,000 compounds in 
addition to a small library of FDA-approved drugs (840 
compounds). This led to the identification of two compounds 
namely STOCK1S-14279 (IC50 = 0.26 µM, Kd = 0.77 µM) and 
Closantel (IC50 = 0.7 µM) (Figure 7).
[25]  
In vitro, both molecules bind to SPAK and inhibit its catalytic 
activity in the submicromolar concentration.[25] A profiling study 
using the RapidKinase48 panel revealed that they inhibited some 
serine/threonine based kinases at 10 µM.[25] However, in previous 
studies the IC50 measured for these compounds was far lower, 
showing that both compounds at therapeutic concentrations, had 
the ability to be highly specific for SPAK inhibition exclusively. 
Interestingly, these two compounds, STOCK1S-14279 and 
Closantel,  are structurally related and inhibit SPAK kinase activity 
in an ATP-independent manner suggesting that they may act as 
allosteric inhibitors rather than being ATP-competitive 
inhibitors.[25] In mpkDCT and MOVAS cells, these compounds 
elicited a dose dependant inhibition of total and phospho NCC and 
NKCC1. In addition, these compounds had no effects on the 
separate kinase MAPK, even at high concentrations showing that 
their inhibition is specific to SPAK.  
In mice, acute administration of Closantel and STOCK1S-14279 
led to a rapid drop in blood pressure and heart rate within 30 
minutes post administration and significant reduction in the 
phosphorylation of NCC in the kidney and NKCC1 in the aorta.[25] 
However, this effect was short and fully recovered 120 minutes 
after administration. This suggests that this observed effect was 
possibly due to the vasodilation effects of SPAK inhibition rather 
than the diuretic effects. Unlike Closantel, repeated injections of 
STOCK1S-14279 were lethal.[25] Consequently, prolonged 
administration of Closantel caused reduction in the 
phosphorylation of NKCC2, suggesting that it can inhibit not only 
SPAK, but also OSR1.[25] Moreover, by day 7, Closantel did not 
have any effects in decreasing blood pressure and no major 
differences in serum electrolytes were noticed.[25] This may be 
because Closantel was only be effective in hypertensive animals 
and further investigation is therefore needed to validate this. 
Although the study by Kikuchi et al[25] indicates that Closantel and 
STOCK1S-14279 are allosteric inhibitors of SPAK and OSR1 
kinases, their exact binding site remained elusive. Recently, we 
reported[23] that these may also bind the secondary pocket of 
SPAK and OSR1 akin to STOCK1S-50699 (Figure 6). This 
finding was supported by molecular docking studies and pulldown 
experiments. To test this hypothesis of these compounds binding 
to the secondary pocket of SPAK and OSR1, Mehellou and 
colleagues[23] performed in silico screening to identify small 
molecules that bind the secondary pocket of OSR1. This resulted 
in the identification of Rafoxanide, a structurally related 
compound to Closantel (Figure 8). Indeed, this agent was able to 
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Figure 6. Crystal structure of OSR1 CCT showing the primary pocket in 
which the RFQV tetrapeptide from WNK kinases bind and the secondary 
pocket, which is thought to bind small molecules allosteric inhibitors of 
SPAK and OSR1 kinases. Figure was produced by AutoDock Vina using 
OSR1 CCT structure (PDB code: 2V3S).  
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Figure 7. Chemical structures of STOCK1S-14279 and Closantel, two 
SPAK and OSR1 kinase inhibitors, as well as their SPAK/OSR1 inhibition 
potencies. Data shown was taken from Kikuchi E et al[25] and AlAmri MA 
et al[23]. 
          
 
 
 
 
 
inhibit OSR1 Thr185Glu (T185E) in vitro, IC50 = 8.18 µM, in an 
ATP-dependent manner.[23] Rafoxanide was also to inhibit 
endogenous SPAK and OSR1 in cells at concentrations ≤ 15 µM. 
To support the idea of its binding to the secondary pocket, 
Rafoxanide was unable to abolish the binding of the 18-mer 
RFQV peptide, which binds the primary pocket, to endogenous 
SPAK.[23] Akin to STOCK1S-50699, a crystal structure of these 
agents in complex with SPAK or OSR1 C-terminal domain or full 
length would be needed to map the exact binding site of these 
compounds.  
Figure 8. Chemical structure and in vitro OSR1 inhibition activity of 
Rafoxanide, an allosteric SPAK/OSR1 kinase inhibitor. Data was taken 
from AlAmri MA et al[23]. 
2.4. Inhibitors of SPAK/OSR1 binding to MO25 
Since the basal kinase activity of SPAK and OSR1 is significantly 
increased by 80-100 fold following the binding to the adaptor 
protein MO25,[5] this protein-protein interaction represents an 
interesting target for the inhibition of SPAK and OSR1 kinases. 
Admittedly, such approach would only result in the inhibition of the 
MO25-dependent activation of SPAK and OSR1 while their basal 
kinase activity would be retained. However, this maybe 
favourable in the clinical indication being targeted, hypertension, 
as a tuning of blood pressure is what is desirable rather than 
robust reduction that may lead to hypotension.  
Targeting this protein-protein interaction has been pursued by the 
discovery of small molecules that bind MO25 and hence inhibit its 
ability to bind and activate SPAK and OSR1 kinases. For this, a 
fluorescence polarisation that employed a 16-mer peptide, which 
contains a WEW motif derived from SPAK that is known to 
mediate the binding to MO25[5], was developed.[26] This assay was 
used in screening a library of ca. 4000 compounds and this led to 
the identification of HK01 as a binder of MO25 (Kd = 127 ± 6 µM) 
(Figure 9).[26]  
 
Figure 9. Chemical structure of HK01, a small molecule MO25 binder. 
Data was taken from Kadri H et al[26]. 
 
 
Notably, this compound was able to inhibit the 16-mer WEW 
peptide binding to MO25 in vitro (IC50 = 78 ± 4 µM).
[26]
 Further 
characterisation showed that HK01 was able to inhibit the MO25 
dependent activation of OSR1 Thr185Glu in vitro and in cells.[26]  
Although HK01 lacked potency, it provided a compelling evidence 
that the scaffolding protein MO25 is amenable to targeting by 
small molecules and such binders can lead to the indirect 
inhibition of SPAK and OSR1 kinases in vitro and in cells. 
3. Conclusion and Future Outlook  
The discovery of WNK genetic mutations in humans causing an 
inherited form of hypertension inspired the decoding of the WNK-
signaling pathway. Such endeavor has led to the identification of 
a series of molecular targets within the WNK-SPAK/OSR1 
signaling cascade that could be targeted for discovering new 
agents that lower blood pressure. Indeed, numerous compounds 
that inhibit some of these kinases or protein-protein interactions 
within this signaling pathway have been reported. The most 
advanced of these are the WNK kinases inhibitors. However, 
achieving exquisite selectivity across the four human WNK 
isoforms has so far proved to be difficult especially for ATP-
competitive WNK inhibitors. This may explain the undesired 
adverse effects observed with WNK463 that did not support its 
further development. Pursuing WNK kinases inhibition via the 
discovery of allosteric inhibitors maybe more promising than the 
ATP-competitive ones. This is due to the fact that achieving high 
potency and excellent PK profiles with non-ATP competitive WNK 
inhibitors has been shown to be possible and even good 
selectivity profiles across the four different WNK isoforms has 
been achieved as it was the case with compound 4 (Figure 3c). 
Nevertheless, the challenges arising from achieving excellent 
selectivity across the four human WNK kinase isoforms may shift 
the focus onto SPAK and OSR1 kinases since animal models 
have supported their targeting for lowering blood pressure and 
achieving selectivity towards one or two of these enzymes may 
not be as difficult as achieving selectivity across the four WNK 
isoforms. To date, no selective SPAK and OSR1 ATP-competitive 
inhibitors have been reported, but many allosteric inhibitors have 
emerged. These largely act by binding to SPAK and OSR1 highly 
conserved CCT domains and as a result act as allosteric inhibitors 
or prevent SPAK and OSR1 binding to WNK kinases. Admittedly, 
the potency of these compounds is yet to reach the levels 
achieved by the reported WNK kinases inhibitors. Hence, there is 
an opportunity for the discovery of SPAK/OSR1 inhibitors that 
potently and selectively inhibit SPAK/OSR1 kinases activity and 
have excellent drug-like properties. Additionally, the promise of 
selectively targeting MO25 and inhibiting its binding and hence 
activation of SPAK and OSR1 kinases is yet to be fully explored. 
This approach may yield potent indirect SPAK and OSR1 kinase 
inhibitors, but the off-target effects of such molecules remains 
unclear especially with regard to their impact on LKB1:STRAD[27] 
signaling of which MO25 is an integral component. 
Given that WNK-SPAK/OSR1 signaling controls electrolyte 
balance in vivo and this expands beyond regulating blood 
pressure, e.g. controlling neuronal hyperexcitability[28] and cell 
volume[29], the impact of WNK-signaling inhibitors on these 
physiological processes remains largely unexplored. Such 
studies would offer an insight into the possible side effects of 
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WNK-signaling inhibitors and may provide new indications that 
could be treated with this class of molecules. 
In conclusion, there is no doubt that a significant progress towards 
the discovery of WNK-signaling inhibitors as new 
antihypertensive drugs has been achieved. With more structural 
biology and medicinal chemistry focus on this important signaling 
cascade, there will be new WNK-signaling kinase inhibitors being 
discovered in the future, some of which would hopefully be 
developed into novel, effective and safe drugs for the treatment 
of hypertension. 
Keywords: WNK • SPAK • Kinase • Inhibition • Hypertension 
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MINIREVIEW 
Various 
components of the WNK-signalling cascade have been validated in vivo as viable 
molecular targets for the discovery of new antihypertensive drugs. Inspired by this, 
a selection of kinase and protein-protein interaction inhibitors, which have shown 
great promise in lowering blood pressure in vivo, have so far been reported. In this 
Minireview, we provide an insight into the discovery the various reported WNK-
signalling inhibitors and offer an outlook into the future of targeting the WNK-
signalling pathway. 
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